psalexa
SearchBar Icon

Order Summary & Billing Information

Order Summary
GO BACK TO REPORT PAGE
Report Title

Biosimilars Market By Product (Recombinant Glycosylated Proteins [Monoclonal Antibodies, Erythropoietin, Follitropin], Recombinant Non-Glycosylated Proteins [Insulin, Recombinant Human Growth Hormone, Granulocyte-Colony Stimulating Factor, Interferons], Recombinant Peptides), By Technology (Monoclonal Antibody, Recombinant DNA, Bioassays, Nuclear Magnetic Resonance, Electrophoresis), By Indication (Oncology, Rheumatology, Blood-Related Disorders, Auto-Immune Diseases, Chronic Diseases, Infectious Diseases, Growth Hormone Deficiency), By Manufacturing Type (Contract, In-House), By Route of Administration (Intravenous, Subcutaneous, Intranasal), by Geography (Germany, France, U.K., Italy, Spain, Sweden, Russia, Switzerland, Austria, Netherlands, Belgium, Norway, China, Japan, India, South Korea, Singapore, Australia, Thailand, Indonesia, Malaysia, U.S., Canada, Brazil, Mexico, Argentina, Columbia, U.A.E., Israel, South Africa, Saudi Arabia) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2014–2024

License

Single User License

Price

$5100

Billing Information

Clicking Proceed to Secure Checkout means that you agree to the P&S Intelligence's terms & conditions.